RETROVIR, HIVID, SAQUINAVIR AIDS REGIMEN
Executive Summary
RETROVIR, HIVID, SAQUINAVIR AIDS REGIMEN will be one of four three-component regimens to start into clinicals under the sponsorship of the Intercompany Collaboration on AIDS Drug Development. Hoffmann-La Roche International R&D President Juergen Drews, MD, announced the first regimens for the collaborative project at a meeting of the National Task Force on AIDS Drug Development, held April 14 in Arlington, Va.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth